This paper will examine the landscape of DDR-associated gene mutations in pancreatic adenocarcinomas and therapeutic development of drugs targeting the process, with a focus on cancers with both germline and somatic alterations in BRCA1 and BRCA2 and cases with mutations in DDR genes other than BRCA1 and BRCA2. This evidence concerns the gene BRCA1 and cancer.